title: [Management of angiotensin-converting enzyme inhibitor-related angioedema: recommendations from the French National Center for Angioedema].
abstract: Angiotensin-converting enzyme (ACE) inhibitor-related angioedema (AE) may be fatal in the absence of specific treatment. No consensus for this side effect currently exists. Also, the French national reference centre for angioedema (CREAK) decided to establish recommendations, developed by an expert group and proposed at a national meeting. A scientific committee conducted a comprehensive literature review and worked out with proposals. These proposals were submitted to a vote to the expert panel of CREAK at a national meeting. Proposals that had received the majority were retained. Diagnosis of ACE inhibitor-related AE is based on clinical events. Regarding the severity of the disease, this diagnosis has to be put forward in any patient currently treated with or who has been treated with ACE inhibitors in the previous 6 months. The diagnosis is important because AE does not respond to usual treatment of histamine-induced AE (antihistamines, corticosteroids, and epinephrine), but only to specific treatment of bradykinin-induced AE, as antagonists of bradykinin or concentrates of C1 inhibitor. The subsequent use of ACE is strictly contra-indicated. A report to pharmacovigilance centres of every case is essential. These recommendations should improve the standardization of the management of ACE inhibitor-related AE.
authors: Allergologie et immunologie clinique, centre hospitalier Lyon-Sud, hospices civils de Lyon, 69495 Pierre-Bénite, France.
authors: A
authors: A
authors: Nosbaum
authors: L
authors: L
authors: Bouillet
authors: B
authors: B
authors: Floccard
authors: N
authors: N
authors: Javaud
authors: D
authors: D
authors: Launay
authors: I
authors: I
authors: Boccon-Gibod
authors: O
authors: O
authors: Fain
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000799:Angioedema / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy*; D057911:Angiotensin Receptor Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects*; D001920:Bradykinin / Q000031:analogs & derivatives / Q000378:metabolism / Q000627:therapeutic use; D065168:Bradykinin Receptor Antagonists; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000009:adverse effects; D005602:France; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects
chemical_list: D000319:Adrenergic beta-Antagonists; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D065168:Bradykinin Receptor Antagonists; D054873:Dipeptidyl-Peptidase IV Inhibitors; D007166:Immunosuppressive Agents; C065679:icatibant; D001920:Bradykinin